![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1461446
¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ(Sevoflurane) ½ÃÀå : ¿ëµµº°, À¯Åëä³Îº°, Áö¿ªº° ½ÃÀå ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2024-2031³â)Sevoflurane Market, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031 |
¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀåÀº 2024³â¿¡ 4¾ï 70¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£ Áß(2024-2031³â)¿¡ 4.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
º¸°í ´ë»ó ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2023 | 2023/2024³â ½ÃÀå ±Ô¸ð | 4¾ï 70¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2019-2023³â | ¿¹Ãø ±â°£ | 2024-2031³â |
¿¹Ãø ±â°£ 2023/2024-2030/2031 CAGR: | 4.40% | 2030/2031³â ¿¹ÃøÄ¡ | 5¾ï 4,220¸¸ ´Þ·¯ |
¼¼º¸Ç÷ç¶õÀº ´ÞÄÞÇÑ Çâ±â¿Í ºÒ¿¬¼ºÀÇ °íºÒ¼ÒÈ ¸ÞÆ¿À̼ÒÇÁ·ÎÆÄÀÏ ¿¡Å׸£À̸ç, Àü½Å ¸¶ÃëÀÇ µµÀÔ°ú À¯Áö¸¦ À§ÇÑ ÈíÀÔ ¸¶ÃëÁ¦·Î »ç¿ëµË´Ï´Ù. µ¥½ºÇ÷ç¶õ¿¡ À̾î ÁïÈ¿¼ºÀÌ ÀÖ´Â Èֹ߼º ¸¶ÃëÁ¦ÀÔ´Ï´Ù.
°¢ ½ÃÀåÀº ÈíÀԱ⿡ ÀÇÇÑ ¸¶Ãë Àü´Þ¿¡ µµ¿òÀÌ µÇ´Â ½Å±â¼úÀÇ ÅõÀÔ¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù ¼¼°è ÀÇ·á ±â¼úÀÇ ¼±µÎ ±â¾÷ÀÎ GE Healthcare´Â Aisys CS2 Anesthesia Delivery SystemÀÇ Àü½Å ¸¶Ãë Àü´ÞÀ» À§ÇÑ ¿£µåŸÀ̵å(Et) Á¦¾î ¼ÒÇÁÆ®¿þ¾î°¡ ¹Ì±¹ ½ÄǰÀǾ౹(FDA))·ÎºÎÅÍ ½ÃÆÇÀü ½ÂÀÎ(PMA)À» ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¹Ì±¹¿¡¼ GE HealthCare´Â Á¾¸» ³óµµ Á¦¾î¸¦ ÅëÇÑ Àü½Å ¸¶Ãë Á¦°øÀ» ½ÂÀÎÇÑ À¯ÀÏÇÑ Á¦Á¶¾÷üÀÔ´Ï´Ù.
¸¶Ãë°¡ ÇÊ¿äÇÑ ¹Ì¿ë ¼ö¼ú Áõ°¡´Â ¼¼°è ¼¼º¸Ç÷ç¶õ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù, ¾ó±¼°ú ¸öÀÇ ¹Ì¿ë ¼ºÇü ¼ö¼ú°ú ¹Ì¿ë ÀÇ·á¿¡¸¸ Æ¯ÈµÈ ¼¼°è À¯¼öÀÇ ÇùȸÀÎ The Aesthetic Society´Â ¸Å³â Ç×·ÊÀÇ Aesthetic Plastic Surgery Statistics(¹Ì¿ë ¼ºÇü ¼ö¼ú Åë°è)¸¦ ¹ßÇ¥Çϰí, ÀÌ ÇùȸÀÇ »õ·Ó°í ´õ Á¤È®ÇÑ µðÁöÅÐ ±â¼úÀ» »ç¿ëÇÏ¿© ¾òÀº µ¥ÀÌÅÍ´Â ¹Ì±¹¿¡¼ 2021³â¿¡ ¹Ì¿ë ¼ºÇü ¼ö¼úÀÌ Áõ°¡ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¾ó±¼, °¡½¿, ½Åü ¼ö¼úÀÌ Å©°Ô ´Ã¾î³µ½À´Ï´Ù. º¹ºÎ¼ºÇü¼ú, µÐºÎÁõ´ë¼ú, Áö¹æÈíÀÔ¼úÀº ¸ðµÎ ¹Ì±¹¿¡¼ 2020³â ÀÌÈÄ ÀαⰡ 63% ±Þ»ó½ÂÇϰí ÀÖ½À´Ï´Ù. dzÈä¼ú, dzÈä/¹ö½ºÆ®¸®ÇÁÆ®, ¹ö½ºÆ®¸®ÇÁÆ®/Ãà¼Ò¼úÀº ¸ðµÎ 48% Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÈíÀÔ ¸¶ÃëÁ¦¸¦ Àç»ç¿ëÇÏ´Â ±â¼úÀÇ Ãâ½Ã°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 7¿ù ¹«±Õ¾àÁ¦ÀÇ Á¦Á¶¿Í °ø±ÞÀ¸·Î ¼¼°è¸¦ ¼±µµÇÏ´Â Baxter International Inc.´Â ÀÇ·á±â¼ú±â¾÷ÀÎ ZeoSys Medical°ú ¸¶Ãë°¡½º¸¦ Æ÷ÂøÇÏ¿© ÀçÀÌ¿ëÇÏ´Â ±â¼úÀ» »óǰÈÇÔÀ¸·Î½á Á¤½Ä ÇÕÀÇ Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Baxter´Â º» °è¾à¿¡ ÀǰÅÇÏ¿© Àü ¼¼°è ÆÇ¸Å±Ç°ú À¯·´ ÀÌ¿ÜÀÇ º» ±â¼úÀÇ »ó¾÷È¿¡ °üÇÑ µ¶Á¡Àû ¶óÀ̼±½º¸¦ °¡Áö°í ÀÖÀ¸¸ç, ZeoSys Medical»ç¸¦ ÀμöÇÏ´Â µ¶Á¡Àû ¿É¼Ç±ÇÀ» °¡Áö°í ÀÖ½À´Ï´Ù.
The global sevoflurane market is estimated to be valued at USD 400.7 Mn in 2024 and is expected to exhibit a CAGR of 4.4% during the forecast period (2024-2031).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2023/2024: | US$ 400.7 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 4.40% | 2030/2031 Value Projection: | US$ 542.2 Mn |
Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for general anesthesia induction and maintenance. It is the fastest-acting volatile anesthetic after desflurane.
Market players are focused on launching new technology to help delivery of anesthesia through inhalers, this could contribute to the growth of the global sevoflurane market over the forecast period. For instance, in April 2022, GE Healthcare, a leading global medical technology company, announced that its end-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). In the U.S., GE Healthcare is the only manufacturer approved to provide general anesthesia with end-tidal concentration control.
Increasing number of aesthetic surgeries requiring anesthesia, is expected to drive the growth of global sevoflurane market. For instance, in April 2022, The Aesthetic Society, world's leading association dedicated solely to facial and body aesthetic plastic surgery and cosmetic medicine issued its annual Aesthetic Plastic Surgery Statistics, which revealed that aesthetic plastic surgery increased in 2021 in U.S. owing to data acquired using the Society's new, more accurate digital technology. The data shows a large growth in procedures for the face, breasts, and body. Abdominoplasty, buttock augmentation, and liposuction have all seen a 63% surge in popularity since 2020 in U.S. Breast augmentation, augmentation/breast lift, and breast lift/reduction treatments all increased by 48%.
Increasing launches of technology to recycle inhaled anesthetics is expected to fuel the growth over forecast period. For instance, in July 2020, Baxter International Inc., a global leader in the production and delivery of sterile medications, announced a formal agreement with ZeoSys Medical, a medical technology company, to commercialize technology to capture and recycle anesthetic gases. Baxter will have worldwide distribution rights and an exclusive license to commercialize the technology outside of Europe, as well as an exclusive option to acquire ZeoSys Medical, under the terms of the agreement.